NextCure, Inc. (NXTC) stock analysis

Healthcare · Biotechnology

From the 10-K filed 2026-03-05

What protects it: the moat

Its defense rests on a portfolio of over 40 patents and exclusive licenses for SIM0505 and LNCB74, with expirations starting in 2039 and 2044.

The company relies on exclusive, worldwide licenses (excluding China and specific territories) for its lead candidates. Protection is built on specific binding epitopes and proprietary linker technologies like the ConjuAll platform.

As of late 2025, the portfolio includes over 40 granted or pending patents. The FIND discovery platform, licensed from Yale, provides the biological basis for identifying these targets, with underlying method-of-use patents expected to expire no earlier than 2036.

About NextCure, Inc.

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures. The company also develop SIM0505, a novel antibody-drug conjugate (ADC) targeting CDH6 (cadherin-6 or K-cadherin) for the treatment of solid tumors. The company was incorporated in 2015 and is headquartered in Baltimore, Maryland.

Other companies in Biotechnology